Goods & Services

Organoid culture media for use in scientific research; cell culture media for use in scientific research; biological tissue cultures, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes; reagents for use in biotechnology; cell culture reagents for scientific and research use; biochemicals for in vitro and in vivo scientific use; cells for scientific or laboratory purposes; stem cells, other than for medical or veterinary purposes; protein preparations for scientific or laboratory purposes; diagnostic gene or protein biomarkers for analyzing proteins for scientific or laboratory purposes; chemical preparations for analyses in laboratories, other than for medical purposes; proteins for use in food industry; protein for use in the manufacture of cosmetics.

Abstract

The present invention relates to a method for evaluating an efficacy of an anticancer drug or an anticancer drug candidate, comprising the step of treating a mixture of cancer organoids and immune cells with the anticancer drug or the anticancer drug candidate. In addition, it relates to the anticancer drug efficacy evaluation system or anticancer drug screening system comprising cancer organoids and immune cells. The present invention relates to a method for evaluating an efficacy of an anticancer drug or an anticancer drug candidate, comprising the step of treating a mixture of cancer organoids and immune cells with the anticancer drug or the anticancer drug candidate. In addition, it relates to the anticancer drug efficacy evaluation system or anticancer drug screening system comprising cancer organoids and immune cells. The mixture of cancer organoids and immune cells according to the present invention is mixed in a specific ratio, and accordingly can similarly reproduce a tumor microenvironment in which cancer cells exist in the body. Therefore, it can make it possible to accurately predict the efficacy of the drug when administered to a subject.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a medium composition for preparing a cancer organoid. In addition, the present invention relates to: a method for preparing a cancer organoid, comprising a step of culturing using the medium composition; and a cancer organoid prepared by the preparation method. A medium for preparing a cancer organoid according to the present invention can promote proliferation of the cancer organoid and maintain stemness of the cancer organoid. Accordingly, the medium can be used to prepare cancer organoids of uniform quality in large quantities within a short period of time, and the cancer organoids prepared with the medium can also be used to directly observe effects on cancer cell proliferation/metastasis and anticancer drug resistance, and can be used in the development of a drug screening platform to check patient-specific anticancer drug resistance in advance. In addition, observation of gene expression regulation according to drug treatment can contribute to the study of molecular mechanisms for the purpose of cancer treatment.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a medium composition for preparing a salivary gland organoid. Also, the present invention relates to: a method for preparing a salivary gland organoid, comprising a step of culturing salivary gland-derived cells in the medium composition; and a salivary gland organoid prepared by the preparation method. A medium for preparing a salivary gland organoid, according to the present invention, can promote the proliferation of a salivary gland organoid, maintain the stemness of the salivary gland organoid, and increase engraftment capability. Therefore, the medium can be used to prepare a large amount of salivary gland organoids with excellent quality, and salivary gland organoids prepared using the medium can be used as a preventive or therapeutic agent for salivary gland-related diseases, an alternative to animal experimental models for salivary gland-related diseases, or the like.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/55 - Glands not provided for in groups , e.g. thyroids, parathyroids or pineal glands
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Abstract

2α2α2α2α2α2α2α analogue, according to the present invention, can exhibit the effect of treating or preventing kidney damage caused by antibiotics. Particularly, since the effect can be achieved without influencing the antibacterial effectiveness of antibiotics, the composition can be effectively used as a material for treating, alleviating or preventing kidney diseases.

IPC Classes  ?

• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Goods & Services

Organoid culture media for use in scientific research; cell culture media for use in scientific research; biological tissue cultures, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes; reagents for use in biotechnology; cell culture reagents for scientific and research use; biochemicals for in vitro and in vivo scientific use; cells for scientific or laboratory purposes; stem cells, other than for medical or veterinary purposes; protein preparations for scientific or laboratory purposes; diagnostic gene or protein biomarkers for analyzing proteins for scientific or laboratory purposes; chemical preparations for analyses in laboratories, other than for medical purposes; proteins for use in food industry; protein for use in the manufacture of cosmetics.

Abstract

The present invention relates to: a method for evaluating the efficacy of an anticancer drug using a mixture of peripheral blood mononuclear cells (PBMCs) and cancer organoids; a method for screening the anticancer drug; a system for evaluating the efficacy of the anticancer drug; or a system for screening the anticancer drug. Specifically, the present invention relates to: a method for evaluating the efficacy of an anticancer drug using a mixture of cytotoxic T cells differentiated from PBMCs and cancer organoids; a method for screening the anticancer drug; a system for evaluating the efficacy of the anticancer drug; or a system for screening the anticancer drug. The method for evaluating the efficacy of an anticancer drug, the screening method, the efficacy evaluation system, or the screening system according to the present invention can very closely reproduce a tumor microenvironment, which is the form in which cancer cells exist in a living body. In addition, since PBMCs derived from a normal individual are used through differentiation into cytotoxic T cells specific to a cancer patient, the burden of collecting biological samples such as blood and tissue samples from the cancer patient can be reduced, and the efficacy of an anticancer drug can be evaluated with high accuracy.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a medium composition for producing nasal mucosal organoids and a method for producing nasal mucosal organoids, the method comprising the step of culturing cells derived from a nasal mucosal tissue in the medium composition. The nasal mucosal organoids produced according to the present invention exhibit high tissue similarity to human nasal mucosal tissues and can be directly infected by viruses such as the coronavirus, or bacteria. Consequently, the method for producing nasal mucosal organoids according to the present invention can be utilized for producing nasal mucosal organoids that closely resemble the morphology and function of biological tissues. Furthermore, the produced nasal mucosal organoids can be beneficially employed for the screening or efficacy evaluation of treatments/vaccines against viral or bacterial infections.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a method for preparing pancreatic cancer organoids mimicking a cancer microenvironment. In addition, the present invention relates to a method for evaluating the efficacy of pancreatic cancer organoids prepared by the above preparation method and an anticancer agent using the pancreatic cancer organoids, and a screening method. The preparation method according to the present invention can prepare pancreatic cancer organoids that perfectly mimic a cancer microenvironment. Accordingly, the pancreatic cancer organoids prepared by the above method can directly observe the effects on cancer cell proliferation/metastasis and anticancer agent resistance, and can be used to develop a drug screening platform to confirm patient-specific anticancer agent resistance in advance. In addition, observation of gene expression regulation according to drug treatment can contribute to the study of molecular mechanisms for the purpose of cancer treatment.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a medium composition for preparing an intestinal organoid. In addition, the present invention relates to: a method for preparing an intestinal organoid, comprising a step of culturing using the medium composition; and an intestinal organoid prepared by the preparation method. The medium for preparing an intestinal organoid can promote the proliferation of the intestinal organoid and maintain the stemness of the intestinal organoid. Therefore, the medium can be used in preparing a large amount of intestinal organoids of excellent quality, and intestinal organoids prepared using the medium can be used as agents for preventing or treating intestine-associated diseases, alternatives to animal experimental models of intestine-associated diseases, and the like.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to a lacrimal gland organoid preparation method. In addition, the present invention relates to: a lacrimal gland organoid prepared by the preparation method; a formulation for preventing or treating dry eye disease, the formulation including the lacrimal gland organoid; and a method for screening a material for preventing or treating dry eye disease using the lacrimal gland organoid. The lacrimal gland organoid prepared according to the present invention has high tissue similarity with human lacrimal gland tissue and excellent tear secretion ability, and in particular, can regenerate damaged lacrimal gland tissue to normalize tear secretion ability when transplanted in vivo. Accordingly, the lacrimal gland organoid preparation method according to the present invention can be used to prepare a lacrimal gland organoid that is similar in shape and function to living tissue, and the prepared lacrimal gland organoid can be used as a material for treating dry eye disease such as Sjogren's syndrome or corneal xerosis or effectively utilized as a method for screening a material for treating dry eye syndrome.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/24 - MucusMucous glandsBursaSynovial fluidArthral fluidExcretaSpinal fluid
• A61P 27/02 - Ophthalmic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present disclosure relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising an intestinal organoid and a TNFα inhibitor. The combination use of the intestinal organoid and TNFα inhibitor according to the present disclosure can alleviate symptoms of inflammatory bowel disease such as weight loss, diarrhea, and bloody stool, and can inhibit fibrosis of the intestinal mucosa due to inflammation. In particular, when the intestinal organoid and the anti-inflammatory TNFα inhibitor are used in combination, the therapeutic effect is significantly superior to that of multiple administrations of the TNFα inhibitor, and thus it can be usefully used as an agent for preventing or treating inflammatory bowel disease.

IPC Classes  ?

• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

Abstract

The present invention relates to a composition comprising an inhibitor of herpesvirus entry mediator (HVEM) or its ligand and a heat shock protein (HSP) inhibitor for treating or preventing cancer. The use of an inhibitor of HVEM or its ligand and an HSP inhibitor in combination exhibits a synergistic effect on anticancer activity, compared to the use thereof singly, and shows an effect within as fast as 72 hours after administration. Therefore, the use of an inhibitor of HVEM or its ligand and an HSP inhibitor in combination can be advantageously utilized for preventing or treating cancer.

IPC Classes  ?

• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method for evaluating efficacy of an anticancer agent or an anticancer agent candidate, the method comprising a step of treating a mixture of a cancer organoid and immune cells with an anticancer agent or an anticancer agent candidate. In addition, the present invention relates to a system comprising a cancer organoid and immune cells for evaluating the efficacy of an anticancer agent or screening an anticancer agent. With a specific mixing ratio, the mixture of a cancer organoid and immune cells according to the present invention can mimic a tumor microenvironment under which cancerous cells exist in vivo. Therefore, when utilized, the mixture allows for the accurate prediction of the efficacy of a drug administered in vivo.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, the pharmaceutical composition comprising an intestinal organoid and a TNFα inhibitor. The combined use of the intestinal organoid and the TNFα inhibitor, according to the present invention, can alleviate symptoms of inflammatory bowel disease, such as weight loss, diarrhea, and bloody stool, and can inhibit fibrosis of the intestinal mucosa caused by inflammation. In particular, when the intestinal organoid and the TNFα inhibitor, which is an anti-inflammatory agent, are used in combination, a significantly superior therapeutic effect can be exhibited as compared to when the TNFα inhibitor is administered multiple times, and thus, the intestinal organoid and the TNFα inhibitor can be effectively used as substances for preventing or treating inflammatory bowel disease.

IPC Classes  ?

• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present invention relates to a composition for transplantation comprising an organoid, and a use of same. According to one example, using collagen, gelatin or fibrin glue as a scaffold for organoid transplantation results in a high transplantation rate and a high survival rate of organoid as well as desirable stability.

IPC Classes  ?

• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/24 - Collagen
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/38 - Animal cells

Abstract

As a tonsilar organoid preparation method and a use thereof, provided are a tonsilar organoid preparation medium and preparation method, the medium additionally comprising a hepatocyte growth factor (HGF) in TFM while not comprising 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol, and thus tonsilar organoids exhibiting the same physiological activity as that of real tonsilar tissue can be long-term subcultured.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Goods & Services

Conducting early evaluations in the field of new pharmaceuticals; development, analysis and evaluation of medical product; drug discovery services; conducting clinical trials; conducting clinical trials for others; platform as a service; development of implants comprising living tissue; development of cell therapy products; development of cell culture medium; biotechnology services; design services relating to process systems for the biotechnology industry; consultancy in the field of testing, inspection, research of medical products; research and development of new products; materials testing and evaluation; conducting technical project studies; engineering testing; scientific research in the fields of medicine, health and pharmacology; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs.

Goods & Services

Conducting early evaluations in the field of new pharmaceuticals; development, and quality evaluation of medical product; drug discovery services; development of implants comprising living tissue; development of cell therapy products; development of cell culture medium; design services relating to process systems for the biotechnology industry, namely, design and development of new technology for others in the field of biotechnology; consultancy in the field of testing, inspection, research of medical products; research and development of new products; materials testing and evaluation; conducting technical project studies in the field of biotechnology; scientific research in the fields of medicine, health and pharmacology; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs

Abstract

The present invention relates to a composition for culturing organoids and a method for culturing organoids by using the same. Since the present invention includes a compound, which can replace an essential protein component in a conventional medium, consistent stability during organoid culturing can be maintained and culturing can be performed at low cost.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C07D 473/10 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine

Abstract

The present invention relates to a composition for transplantation comprising an organoid, and a use of same. According to one example, using collagen, gelatin, or fibrin glue as a scaffold for organoid transplantation results in a high transplantation rate and a high survival rate of the organoid as well as desirable stability.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/24 - Collagen